It was recently demonstrated that SIRT1 and systemic SRT1720 conferred cardioprotection in a ischemia-reperfusion model.36, 37, 38 Therefore, it may even be feasible to combine pretreatment of MSCs with systemic administration of SRT1720 to provide an optimal therapy for MI. This evidence concerns the gene SIRT1 and myocardial infarction.